The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors

<table class="table-group" id="tab6"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left">Mutation revealed in ET pts with thrombosis</td><td class="align_center">#</td><td class="align_center">%</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">JAK2 V617F</td><td class="align_center">49</td><td class="align_center">80.4</td></tr><tr><td class="align_left">CALR</td><td class="align_center">1</td><td class="align_center">1.6</td></tr><tr><td class="align_left">MPL</td><td class="align_center">1</td><td class="align_center">1.6</td></tr><tr><td class="align_left">Triple negativity</td><td class="align_center">10</td><td class="align_center">16.4</td></tr><tr><td class="align_left">Total</td><td class="align_center">61</td><td class="align_center">100</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>JAK2, CALR, and MPL mutational status in the 61 ET patients with thrombosis.</div>

Advances in Hematology

tab6

Table 6

Table 6: The Essential Thrombocythemia, Thrombotic Risk Stratification, and Cardiovascular Risk Factors 